Jun 13

Artiva Biotherapeutics Celebrates Official Opening of San Diego Corporate Headquarters and R&D Lab Facilities

  • 52,000-square-foot corporate headquarters in San Diego with R&D and GMP manufacturing center
  • Builds on current capability at Artiva’s partner, GC Cell’s facility in Republic of Korea
  • Custom-built GMP manufacturing center further enables Artiva’s leadership position in scaled, off-the-shelf NK and CAR-NK therapeutic manufacturing for treatment of solid and hematological cancers

SAN DIEGO, June 13, 2022 – Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic, natural killer (NK) cell therapies that are safe and accessible to cancer patients, today announced the official opening of the company’s U.S. corporate headquarters and R&D laboratory facilities in San Diego.

The 52,000-square-foot facility will include a multi-suite, custom-built current Good Manufacturing Practices (cGMP) cell production center, to support NK and CAR-NK cell production for Artiva’s pipeline development and clinical trial supply.

“We’re very pleased to welcome our team to this new facility, which was specifically designed to accommodate our growth and to support research and development for our pipeline of optimized NK and CAR-NK cell therapies for the treatment of cancer,” said Fred Aslan, M.D., CEO of Artiva.

The new facility and capabilities will be in addition to Artiva’s continued research and cGMP manufacturing at its partner GC Cell’s state-of-the-art 300,000-square-foot cell center, which was completed in 2018 and comprises research labs, process development labs, and a 50,000-square-foot cGMP cell therapy manufacturing facility in the Republic of Korea.

The combined R&D and manufacturing capabilities of the new San Diego site coupled with GC Cell’s Korean facility supports Artiva’s development of the next generation off the shelf NK-cell therapies for the treatment of solid and hematological cancers.



Photos Caption: Artiva officially opened its San Diego corporate headquarters and NK cell therapy research and GMP manufacturing facility with an employee ribbon cutting. The new 52,000-square-foot facility has research and process development laboratories and will include a multi-suite custom-built Good Manufacturing Practices (GMP) manufacturing center to support NK and CAR-NK cell production for Artiva’s pipeline development and clinical trial supply. The building is located at 5505 Morehouse Drive, San Diego, California. (Photos Credit: Artiva Biotherapeutics, Inc.) 

About Artiva Biotherapeutics

Artiva’s mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, utilizing our Manufacturing-First approach, that are safe and accessible to cancer patients. Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas. Artiva’s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and AB-202, a CD19-specific CAR-NK cell therapy candidate for the treatment of B-cell malignancies. Artiva has entered into therapeutic NK cell collaborations with Merck Sharp & Dohme Corp. and with Affimed GmbH. Artiva’s AlloNK™ platform incorporates cell expansion, activation, and engineering technology developed by Artiva’s strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea. Artiva is headquartered in San Diego. For more information, visit www.artivabio.com.

Contacts

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

Investors: Michael E. Faerm, Artiva Biotherapeutics, Inc., ir@artivabio.com

Recent Posts

See All

Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101

AB-101 is a cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers Granted Fast Track designation by U.S. FDA for the treatment of relapsed/refractory non-Hodgkin lymphoma of B cell origin, in combination with rituximab SAN DIEGO, January 31, 2023 – Artiva Biotherapeutics, Inc., a clinical...

Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

Presentation of preclinical data for AB-101, a clinical-stage, ADCC-enhancer, allogeneic, off-the-shelf NK cell therapy candidate developed with Artiva’s AlloNKTM Platform Data highlights the optimized cell profile of AB-101 and combination data with monoclonal antibodies rituximab, obinutuzumab, cetuximab, and trastuzumab SAN DIEGO, November 10, 2022 – Artiva Biotherapeutics, Inc., a clinical stage company whose mission is...

Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101

Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patients Affimed’s AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patients AB-101 is a clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived NK cell manufactured at large...